Exelixis (EXEL) Set to Announce Earnings on Tuesday

Exelixis (NASDAQ:EXEL - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.29 per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.25 by $0.02. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. The company had revenue of $479.65 million for the quarter, compared to analyst estimates of $481.23 million. On average, analysts expect Exelixis to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Exelixis Price Performance

Shares of Exelixis stock traded up $0.42 on Tuesday, hitting $23.29. 1,917,663 shares of the company's stock traded hands, compared to its average volume of 2,283,314. Exelixis has a one year low of $18.08 and a one year high of $24.34. The company has a fifty day moving average of $22.61 and a two-hundred day moving average of $22.15. The company has a market capitalization of $6.87 billion, a price-to-earnings ratio of 36.39, a price-to-earnings-growth ratio of 0.60 and a beta of 0.54.

Insider Transactions at Exelixis

In related news, Director Alan M. Garber sold 19,205 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the sale, the director now directly owns 35,703 shares of the company's stock, valued at $857,229.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Alan M. Garber sold 19,205 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the sale, the director now directly owns 35,703 shares of the company's stock, valued at $857,229.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Edward Johnson purchased 190,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 21st. The shares were acquired at an average cost of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the transaction, the director now directly owns 1,100,730 shares of the company's stock, valued at approximately $22,785,111. The disclosure for this purchase can be found here. Company insiders own 2.90% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on EXEL. TheStreet upgraded Exelixis from a "c+" rating to a "b-" rating in a research report on Monday, March 18th. Royal Bank of Canada increased their price target on Exelixis from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Wednesday, February 7th. JMP Securities reiterated a "market outperform" rating and issued a $27.00 price target on shares of Exelixis in a report on Wednesday, April 10th. Stifel Nicolaus increased their price target on Exelixis from $23.00 to $25.00 and gave the stock a "hold" rating in a report on Friday, February 2nd. Finally, William Blair reiterated an "outperform" rating on shares of Exelixis in a report on Friday, January 26th. Six research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $26.29.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.